CHINARES PHARMA (03320) announced that on October 29, 2025, CHINARES PHARMA (Shantou) (as the general partner), CHINARES DOUBLE-CRANE (as the limited partner), and CHINARES PHARMA Investment (as the limited partner) (each being a subsidiary of the company), along with other partners, entered into a limited partnership agreement to establish a proposed fund with a scale of RMB 500 million. The fund will primarily invest in high-growth enterprises in the fields of synthetic biology, innovative drugs, and biotechnology. The group intends to commit a total of RMB 123 million, accounting for approximately 24.6% of the fund's total committed capital. Upon establishment, the fund will not be consolidated as a subsidiary of the company. Shenzhen CHINARES Capital has been appointed as the fund manager. Synthetic biology is one of the group's strategic development directions. By establishing the fund, the group aims to build an industrial platform for synthetic biology in Hohhot, optimizing its strategic layout in key related sectors. Additionally, leveraging Hohhot's industrial synergies, the group expects the fund to achieve objectives such as diversifying synthetic biology investment channels, fostering innovation incubation, accelerating product and technology collaborations, and securing commercialization rights. After its establishment, the fund will be recorded as an equity investment in the company's consolidated financial statements.